# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Georgia O'Keeffe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET011-SYN-TD
- Date: 1968-07-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wendell Ashby, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Treat-and-extend retina visit and primary care review of vision rehabilitation. **S**

## History of present illness

Ms. O'Keeffe returns eight weeks after her third injection, the first extended interval. Her left-eye vision has held, with no new distortion, and daily Amsler checks of each eye show no change. Low-vision rehabilitation is complete: task lighting and a stand magnifier are set up in the studio, and high-contrast labels mark her paints and household controls. She is painting daily. The driving assessment cleared her for short local routes by day. She takes the AREDS2 supplement daily and has had no falls. **S**

| Element | Detail |
|---|---|
| Interval change | Left-eye vision stable over eight weeks; no new distortion |
| Amsler grid | Daily checks of each eye; no change |
| Low-vision rehabilitation | Task lighting, stand magnifier, and high-contrast labels in place |
| Driving | Cleared for short local routes by day |
| Function | Painting daily; independent at home; no falls |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No new distortion, blur, pain, flashes, or floaters |
| Constitutional | Negative | Weight stable; good energy |
| Musculoskeletal | Negative | No falls |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

4 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/72 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 56.5 kg; BMI 20.8 kg/m². All vital signs are synthetic.

Best-corrected visual acuity, right eye (ETDRS letters): 77 (low); Best-corrected visual acuity, left eye (ETDRS letters): 70 (low); Central subfield thickness by OCT, left eye: 268 um; Intraocular pressure, right eye: 15 mmHg; Intraocular pressure, left eye: 15 mmHg; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Best-corrected visual acuity, right eye (ETDRS letters): 78 (low) at baseline, 77 (low) at this visit **S**
- Best-corrected visual acuity, left eye (ETDRS letters): 56 (low) at baseline, 70 (low) at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, energetic |
| Visual acuity | Best-corrected 77 letters right and 70 letters left |
| Intraocular pressure | 15 mmHg in each eye before injection |
| Anterior segment | Quiet in both eyes |
| Dilated fundus, left eye | No fluid or hemorrhage |
| Dilated fundus, right eye | Large drusen unchanged; no fluid or hemorrhage |
| OCT, both eyes | Left eye dry, central subfield thickness 268 µm. Right eye large drusen without fluid |
| After injection, left eye | Optic nerve head perfused; counts fingers; no pain |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Neovascular age-related macular degeneration, left eye, inactive on treat-and-extend** (H35.3221). Dry after eight weeks (central subfield thickness 268 µm), with acuity 70 letters, up 15 from baseline. Fourth injection given today without complication. **S**
   - Extend the next interval to ten weeks.
   - Same-day call for new distortion or warning signs.
2. **Intermediate dry age-related macular degeneration, right eye** (H35.3112). Stable: 77 letters, no fluid on OCT, no change on Amsler checks. **S**
   - Continue the AREDS2 supplement, daily Amsler checks, and dilated examination at each retina visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Best-corrected visual acuity (ETDRS letters) | Every injection visit | Completed today | 77 letters right and 70 letters left |
| Imaging | Optical coherence tomography of the macula | Every injection visit | Completed today | Both eyes. Left dry at 268 µm; right drusen without fluid |
| Examination | Intraocular pressure before and after injection | Every injection visit | Completed today | Before injection 15 mmHg in each eye; after injection, optic nerve perfused and counting fingers |
| Examination | Dilated examination of the fellow (right) eye | Every injection visit | Completed today | Large drusen unchanged; no fluid on OCT |
| Examination | Comprehensive dilated eye examination | Every 1 to 2 years at 65 or older | Up to date | Both eyes examined in full at the March retina consultation and again today |
| Medication safety | Intravitreal injection safety | Every injection visit | Completed today | Fourth injection; no complication to date |
| Self-management | Teaching on warning signs of endophthalmitis and retinal detachment | Every injection visit | Completed today | Reviewed again before the ten-week interval |
| Self-management | Daily home Amsler grid, each eye | Daily | Completed today | Daily checks recorded; no change in either eye |
| Medication safety | AREDS2 supplement for intermediate AMD | Daily, long term | Completed today | Taking it daily |
| Referral | Low-vision rehabilitation, with home fall-risk review and a driving assessment | Once central vision is reduced; review as vision changes | Up to date | Completed since the last visit: lighting, magnifier, and labels in place; cleared for short local daytime driving. Review if vision changes |
| Survey | Functional vision assessment (reading, color, driving, work) | At diagnosis; again with change | Completed today | Painting daily with aids; reading with the magnifier; daytime local driving only |
| Survey | Depression screen (PHQ-2) | At follow-up, because vision loss raises the risk of depression; periodically at 65 or older | Completed today | Score 0, down from 1 at intake |
| Survey | Cognitive screen (Mini-Cog) | Annually at 65 or older | Up to date | 5 of 5 at intake in March; next at the annual wellness visit |

## Goal progress

- Gain at least 10 ETDRS letters in the left eye by the end of the loading phase. Outcome by 1968-05-07: Left eye improved from 55 to 69 letters after three injections. **S**
- Dry macula on OCT (central subfield thickness below 300 um, no fluid) by the end of the loading phase. Outcome by 1968-05-07: Central subfield thickness fell from 418 to 274 um with no fluid. **S**
- Check the Amsler grid daily for each eye and report any change the same day. Outcome by 1968-07-02: Daily checks recorded; no new change in the right eye. **S**
- Complete a low-vision rehabilitation evaluation and set up studio lighting and magnification by the July visit. Outcome by 1968-07-02: Task lighting, a stand magnifier, and high-contrast labels in place; still painting daily. **S**

## Guideline basis

- Age-Related Macular Degeneration Preferred Practice Pattern (2024), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026), Aether Forge

## Follow-up

- Retina visit in ten weeks for acuity, OCT, pressure, and the fifth injection. Annual wellness visit in the fall. **S**
- Next scheduled visit 1968-10-15: subsequent annual wellness visit. **S**
